Jubilant Pharmova Ltd.

DUBLIN--( BUSINESS WIRE )--The "Drug Discovery Services - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Drug Discovery Services is estimated at US$48.6 Billion in 2023 and is projected to reach US$61.1 Billion by 2030, growing at a CAGR of 3.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The Medicinal Chemistry Services segment is on a significant growth trajectory, expected to reach US$31.6 billion by 2030 with a CAGR of 4%. The Biology Services segment is also anticipated to grow, albeit at a slower rate, with a 2.8% CAGR over the next seven years. The U.S. market is estimated at $12.9 billion in 2023, while China is forecasted to experience impressive growth with a 6.9% CAGR, reaching $14.1 billion by 2030. Other key regions, including Japan, Canada, Germany, and the Asia-Pacific, are also highlighted for their growth trends. The report features comprehensive market data, providing independent analysis of annual sales and market forecasts in US$ million from 2023 to 2030. It offers in-depth regional analysis, delivering detailed insights into key markets such as the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. The report also includes company profiles of major players like Albany Molecular Research Inc., Charles River Laboratories International Inc., and Domainex, among others. This report is essential for those seeking a detailed market analysis of the Global Drug Discovery Services Market, covering major geographic regions and market segments. It provides competitive insights into the market presence of major players across different geographies and discusses future trends and drivers shaping the industry's future. The report also offers actionable insights that can help identify new revenue opportunities and support strategic business decisions. Additionally, complimentary updates are provided for one year to keep readers informed of the latest market developments. Key Questions Answered: How is the Global Drug Discovery Services Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $48.6 Billion Forecasted Market Value (USD) by 2030 $61.1 Billion Compound Annual Growth Rate 3.3% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Global Economic Update Drug Discovery Services - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) FOCUS ON SELECT PLAYERS (Total 33 Featured) Albany Molecular Research Inc. Charles River Laboratories International Inc. Domainex Eurofins Scientific SE Evotec A.G. GenScript Biotech Corporation Jubilant Biosys Ltd. Laboratory Corporation of America Holdings Pharmaceutical Product Development LLC Piramal Enterprises Ltd. Selvita S.A. Thermo Fisher Scientific Inc. WuXi AppTec For more information about this report visit https://www.researchandmarkets.com/r/usdw54 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Pharmaceutical Contract Manufacturing is estimated at US$112.4 Billion in 2023 and is projected to reach US$159.8 Billion by 2030, growing at a CAGR of 5.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the pharmaceutical contract manufacturing market is driven by several factors, including the rising demand for generic medicines, the increasing complexity of drug production, and the expansion of the biologics market. As patent cliffs lead to increased generic competition, pharmaceutical companies are turning to CMOs to expedite production and capitalize on market opportunities. The complexity of producing new generations of drugs, especially biologics and personalized medicines, also necessitates specialized capabilities that many pharmaceutical firms find more feasible to outsource. Additionally, the shift towards personalized medicine is pushing companies to adapt to flexible and scalable production processes, which contract manufacturers are equipped to handle. These trends, combined with the global push for cost efficiency and faster time-to-market, continue to drive significant growth in this sector, highlighting its critical role in the pharmaceutical industry's supply chain. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Pharmaceutical Contract Manufacturing Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pharmaceutical Contract Manufacturing Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Insights: Market Growth: Understand the significant growth trajectory of the API/Bulk Drugs segment, which is expected to reach US$94.8 Billion by 2030 with a CAGR of a 4.9%. The Advanced Drug Delivery Formulations segment is also set to grow at 4.4% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $33.9 Billion in 2023, and China, forecasted to grow at an impressive 6.4% CAGR to reach $27.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as AbbVie Inc., Aenova Holding GmbH, Catalent Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 528 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $112.4 Billion Forecasted Market Value (USD) by 2030 $159.8 Billion Compound Annual Growth Rate 5.2% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Pharmaceutical Contract Manufacturing - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) Recent Market Activity MARKET TRENDS & DRIVERS Strong Rise in Pharmaceutical Sales to Drive Demand for Pharmaceutical Contract Manufacturing Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025 Emergence of Outsourcing Trend Bodes Well for CDMOs Pharmaceutical Contract Manufacturers Adopt Advanced Manufacturing Technologies Embracing Emerging Technologies Exploring & Exploiting New Technologies for Rich Dividends Rapid Growth of Generic Drugs Drives Demand for Pharma Contract Manufacturing Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025 Increasing Significance of Biologic Drugs Fuels Innovations Supports Demand for Pharmaceutical Contract Manufacturing Market Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025 Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 World Diabetes and Population Statistics (2019, 2030 & 2045) Persistent Increase in Pharmaceutical R&D Bodes Well for PCM Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025 Increasing Sales of OTC Drugs Presents an Opportunity for Pharma Contract Manufacturing Market Increasing Outsourcing of Clinical Trials to Emerging Markets New Technology Promises to Improve Sterile Manufacturing Process Serialization Drives New Design Developments in Pharma Sector FOCUS ON SELECT PLAYERS (Total 192 Featured) AbbVie Inc. Aenova Holding GmbH Catalent Inc. Enteris BioPharma, Inc. Jubilant Pharma Ltd. Kemwell Biopharma Pvt. Ltd. Lifecore Biomedical Lonza Group Ltd. Thermo Fisher Scientific, Inc. WuXi AppTec Co., Ltd. For more information about this report visit https://www.researchandmarkets.com/r/dyxjp5 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Improved supply capabilities of Neuraceq® to provide better patient access to beta-amyloid PET BOSTON, July 9, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma, a global company that offers radiopharmaceuticals and radiopharmacies for nuclear medicine, announce the expansion of their strategic partnership and licensing agreement to provide and distribute Neuraceq® from Jubilant's single photon emission computed tomography (SPECT) and Positron Emision Tomography (PET) radiopharmaceutical manufacturing site located in Mobile, AL. The first doses have been made available on July 9th, 2024. Neuraceq® is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterization of subjects assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases. "Expanding Neuraceq® manufacturing in Mobile in collaboration with Jubilant, further reinforces Life Molecular Imaging's commitment to meeting the increasing demand for amyloid detection to confirm eligibility for new therapies. We are excited to support the growing needs of the customers in the region, and to provide Neuraceq® access for the benefit of physicians, patients, and our pharma partners," said Colleen Ruby, US Country and Chief Operating Officer, Americas and APAC. "More than 6.2 million Americans are currently living with Alzheimer's disease. A progressive brain disorder that impacts memory, thinking and language skills, and the ability to carry out the simplest tasks. The Jubilant Radiopharma Team is excited to bring Neuraceq® to physicians and patients in the Mobile, AL area," said Renato Leite, President, Jubilant Radiopharmacies. "The availability of Neuraceq® offers new hope through the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease." About Neuraceq (florbetaben 18F) Indication Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Neuraceq® scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations. Limitations of Use A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder. Safety and effectiveness of Neuraceq® have not been established for: Predicting development of dementia or other neurologic conditions Monitoring responses to therapies. Important Safety Information Risk for Image Interpretation and Other Errors Errors may occur in the Neuraceq® estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq® images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq® scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq® scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future. Radiation Risk Neuraceq®, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Common Adverse Reactions The overall safety profile of Neuraceq® is based on data from 1,090 administrations of Neuraceq® to 872 subjects. No serious adverse reactions related to Neuraceq® administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq® were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%). For more information please visit: neuraceq.com About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit . About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: | About Jubilant Radiopharma Jubilant Radiopharma, a division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business that comprises development, manufacturing and commercialization of products through its Radiopharmaceuticals business and distribution through its national network of Radiopharmacies. The division's Radiopharmacies business is the second largest radiopharmacy network in the US with 46 pharmacies distributing nuclear medicine products to the largest national Group Purchasing Organisations (GPOs), regional health systems, stand-alone imaging centres, cardiologists and hospitals. This business has over 30 years of experience in serving the US nuclear medicine community and its current geographical reach enables it to serve over four million patients yearly. Jubilant Radiopharma is focused on "Improving Lives through Nuclear Medicine". For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] SOURCE Life Molecular Imaging